As the cornerstone of one of the nation’s leading cancer care and research centers, BWH and BWFH have pioneered advances in surgery, imaging, and targeted therapies that have dramatically improved outcomes for many women with breast cancer. And today, the country’s foremost breast surgical oncologists lead all breast surgery clinical and research efforts across the Brigham community. Tari A. King, MD, directs breast surgery and has nationally recognized expertise in lobular carcinoma in situ (LCIS). Elizabeth A. Mittendorf, MD, PhD, oversees breast surgery research and is a national leader in the development of immunotherapy for breast cancer. Under their direction, our breast cancer experts are collaborating on research across the continuum of care— from prevention and diagnosis to treatment and survivorship. Their discoveries will drive clinical innovation focused on four key priorities: prevention and early disease, patient-centered outcomes, tailored local-regional therapeutic strategies, and tumor immunology. These efforts will rely on a foundation of quality and value; the importance of training and educating the next generation of breast surgical oncologists; and rigorous stewardship of our comprehensive biospecimen collection, which is essential to all our research.
Our robust research enables us to continue to advance ongoing studies and explore new lines of inquiry. Our breast surgeon-scientists collaborate with their clinical and research colleagues across the Brigham community and beyond to pursue rigorous scientific studies that promise to significantly transform breast cancer treatment. These investigations include:
- Laboratory studies of tumor biology and immunologic response mechanisms
- Correlative studies linking tumor types to clinical outcomes (e.g., invasive disease)
- Clinical trials to assess existing and emerging therapies
- PRO studies to validate new clinical care models and document survivorship issues
- AI predictive modeling to improve risk assessment and treatment guidelines